Phase 2 Lung Cancer Trial, Not Yet Recruiting NCT06306560 Sponsor: Harbin Medical University Condition: Lung Cancer
Back to Lung Cancer

Phase 2 Lung Cancer Trial, Not Yet Recruiting

NCT06306560
Not Yet Recruiting Phase 2

voxsanity.com.au · Eligibility summary from public government registries · 18 August 2026 · not medical advice

Who may and may not be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who may be able to join

  • Adults aged 18 to 80 years old, either male or female.
  • People who have been diagnosed with extensive stage small cell lung cancer, confirmed by a laboratory test on a tissue sample.
  • People who have never received any systemic treatment for extensive stage small cell lung cancer.
  • People who have at least one measurable area of cancer that can be tracked using standard imaging guidelines.
  • People whose life expectancy is expected to be more than 3 months.
  • People who are in good general physical condition and able to carry out everyday activities (rated 0–1 on a standard medical performance scale — confirm with trial site if unsure what this means).
  • People whose major organs (such as liver, kidneys, and heart) are functioning normally.
  • Women who could become pregnant must have a negative pregnancy test before starting treatment, and both women who could become pregnant and men who are sexually active with such women must agree to use reliable contraception throughout treatment and for 6 months after the last dose.
  • People who have voluntarily agreed to take part by signing a consent form.

Who may not be able to join

Each point below is a reason the trial team may not be able to accept someone. It is not a list of requirements to meet.

  • People who have had another type of cancer in the past 5 years, unless it was a fully cured skin basal cell carcinoma, cervical carcinoma in situ, or a superficial or non-invasive bladder cancer.
  • People who have an active tuberculosis infection, or who have had tuberculosis in the past.
  • People who have brain metastases (cancer that has spread to the brain) that are not well controlled, or who have a history of serious psychiatric illness that is difficult to manage, or who have severe cognitive or intellectual difficulties.
  • People who have an active autoimmune disease (a condition where the immune system attacks the body), with some exceptions — people with only mild skin conditions not requiring systemic treatment (such as vitiligo, psoriasis, or patchy hair loss) or thyroid conditions managed with hormone replacement alone may still be considered (confirm with trial site).
  • People who have fluid build-up around the lungs, heart, or abdomen that cannot be controlled and requires repeated draining.
  • People who have any severe or uncontrolled medical condition.
  • People whose scans show the tumour is growing into or is too close to major blood vessels.
  • People who have a tendency to bleed easily, a risk of coughing up blood, or a significant history of blood clotting problems.
  • People who have a history of abusing substances such as alcohol or drugs.
  • People who have active hepatitis B or hepatitis C, as determined by specific blood test results being above normal levels.
  • People who are HIV positive.
  • People who are unlikely to be able to follow the trial procedures or attend follow-up visits.
  • People whom the trial doctor believes should not take part, for any reason.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 21 July 2026

Contact this trial

Principal Investigator: Yanbin Zhao, MD, Harbin Medical University Cancer Hosptital

Phone: 13904811741

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Not Yet Recruiting
Phase
Phase 2
Sponsor
Harbin Medical University
Registry
ClinicalTrials.gov
Start date
15 March 2024
Est. completion
15 March 2027

Primary endpoints

6-month progression-free survival

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 21 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov